Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the ...

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in hard-to-treat patients. It’s “a potential breakthrough for a growing cohort of ...

For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs—commonly referred to as antiretroviral therapy—the virus usually rushes ...

Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...

A Q&A With Shauna Applin, ARNP. AJMC: Despite substantial therapeutic advances since the 1980s, the US is not on pace to achieve the goals of the Ending the HIV Epidemic (EHE) public health initiative ...

People infected with HIV must take antiretroviral drugs for life. But engineered antibodies appeared to suppress the virus for certain participants in recent trials in Africa and Europe A digital ...

TACLOBAN CITY – The island town of Biri in Northern Samar has opened an HIV Treatment Hub to strengthen healthcare service delivery for human immunodeficiency virus (HIV) prevention, free testing, ...

In the United States, HIV continues to be a significant cause of morbidity and mortality. In 2023, more than 39,000 people were diagnosed with HIV, and approximately 4,500 people died from causes ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented ...